Pelage制药公司在取得积极阶段2a的结果后,将PP405药物的脱毛专题试验推进到第3阶段试验。 Pelage Pharmaceuticals advances its topical hair loss drug PP405 to phase 3 trials after positive phase 2a results.

Pelage制药公司正在推进其专题治疗PP405,一种治疗发型损失的一流疗法,在积极阶段2a后进入第3阶段试验,结果显示安全性得到提高,头发生长得到有意义的改善。 Pelage Pharmaceuticals is advancing its topical treatment PP405, a first-in-class therapy for pattern hair loss, into phase 3 trials after positive phase 2a results showed safety and meaningful hair growth improvement. 治疗以休眠发泡干细胞为对象,通过代谢开关,与目前的治疗方法不同,目前的治疗只是减慢掉发。 The therapy targets dormant hair follicle stem cells via a metabolic switch, differing from current treatments that only slow hair loss. 该公司在B系列资金中以1.2亿美元作为后盾,计划扩大测试范围,以覆盖更多人口和其他形式的头发损失。 Backed by $120 million in Series B funding, the company plans to expand testing to larger populations and other forms of hair loss. 全球抗无意义寡核酸市场在2025年达到25亿美元,在瘤学中使用越来越多,尽管交付挑战和毒性仍然是障碍. The global antisense oligonucleotide market reached $2.5 billion in 2025, with growing use in oncology, though delivery challenges and toxicity remain hurdles.